FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
8 letters match. Newest first.
-
DrugsPratik Doshi, M.D. / Alembic Pharmaceuticals Ltd.
FDA warned investigator Dr. Pratik Doshi at Alembic's Vadodara site that a bioequivalence study consent form wrongly said nothing was experimental.
High risk -
BiologicsAdnan Dahdul, MD
FDA warns clinical investigator Dr. Adnan Dahdul over consent, eligibility and record failures in a biologics study.
High risk -
DrugsNaseem A. Jaffrani, M.D.
FDA says clinical investigator Dr. Naseem Jaffrani failed to report serious adverse events to sponsors within 24 hours in two drug trials.
High risk -
DrugsMukesh B. Chandre, M.D., MBBS/Ashirwad Hospital & Research Centre
FDA warned clinical investigator Dr. Mukesh Chandre over informed consent failures in a doxorubicin liposome bioequivalence study.
High risk -
DrugsMark S. Dacey, M.D.
FDA warns Dr. Mark S. Dacey that a trial subject underwent an optional eye-fluid sampling procedure after twice declining consent.
High risk -
DrugsCenter For Immunology Science, LLC
FDA cites Center for Immunology Science for a clinical trial of heat-killed Mycobacterium smegmatis without an Investigational New Drug application.
High risk -
DrugsProdrome Sciences USA, LLC
Prodrome Sciences studied its supplement ProdromeNeuro Oil as a dementia drug in 29 people without first filing an IND, FDA says.
High risk -
DrugsDevalingam Mahalingam, M.D., Ph.D.
FDA warns clinical investigator Devalingam Mahalingam, M.D., Ph.D. over a 100-fold investigational drug overdose that led to a subject's death.
High risk